Table 3.

Some of the compounds under development as anti-splicing HIV therapies

Compound	Activity	Reference
SR protein targeting treatments
Tetracyclic indole molecule (IDC16)	Inhibiting the splicing activity of ASF	48
DHA-type compound 9 (1C8)	Inhibiting the splicing activity of ASF	48
Isonicotinamide compound SRPIN340	Inhibitor of the SR protein kinases SRPK1 and SRPK2
Rev targeting treatments
Aminoglycoside antibiotics	Inhibit the association of Rev with RRE	32
Aromatic heterocyclic compounds	Inhibit the association of Rev with RRE	32
Clomiphene	Targets the formation of Rev-RRE	49
8-Azaguanine	Target the formation of Rev-RRE	50,55
2-(2-[5-Nitro-2-thienyl]vinyl)quinolone	Target the formation of Rev-RRE	50,55
Indole derivative KH-BD19	CLK inhibitory activity	55
Digoxin	Over-splicing of HIV mRNA and blocking Rev expression	50
Tat targeting treatments
Antisense U7snRNP	Tat/Rev exon skipping	10
RNA binding domain of ASF	Competing with Tat for binding the TAR domain	53
Dominant negative forms of Tat	Inhibit Tat function	52
MCEF fragments	Repress RNA polymerase II transcription of HIV-1 LTR-directed Tat-transactivation	46

Note: This table lists some of the compounds that are currently being assessed as anti-HIV drugs due to their ability to interfere with or block HIV mRNA splicing.

Abbreviations: DHA, diheteroarylamide; RRE, Rev response element; TAR, transactivating response region; LTR, long terminal repeat.